Adaptimmune
As of the edition of 20 October 2026, Adaptimmune runs 5 drugs, 1 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 2 company names in this family.
- TCR2 Therapeutics: acquired in 2023; successor Adaptimmune Limited
Drugs by status
| Status | Count |
|---|---|
| Marketed | 1 |
| Stopped | 4 |
| Total | 5 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Afamitresgene autoleucel | Ends 2036 (reference-product exclusivity) | 1 |
A route B row is one company at one target.
Where its trials are
- Cancer: 4 trials led
- Lungs and airways: 2 trials led
- Digestive system: 1 trials led